Cardiovascular diseases in patients after hematopoietic stem cell transplantation: Systematic review and Meta-analysis - 03/02/23

Doi : 10.1016/j.retram.2022.103363

Azin Alizadehasl ^a, Nashmil Ghadimi ^a, Hossein Hosseinifard ^b, Kamran Roudini ^c, Amir Hossein Emami ^d, Ardeshir Ghavamzadeh ^e, Davood khoda-Amorzideh ^a,^⁎
^a Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
^b Research Center for evidence-based medicine (rcebm), Tabriz University of Medical Sciences, Tabriz, Iran
^c Department of internal medicine, Hematology and Medical oncology ward, Cancer research center, cancer institute, Imam Khomeini hospital complex, Tehran University of medical sciences, Tehran, Iran, Islamic republic of Iran
^d Department of internal Medicine, school of medicine cancer institute, Imam Khomeini Hospital Tehran University of Medical Sciences
^e Cancer & cell Therapy Research Center, Tehran University of medical Scinces Tehran

^⁎Corresponding author.

Abstract

Background

Hematopoietic Stem Cell Transplantation (HSCT), is performed to treat many malignancies such as autologous or allogenic. Despite the success of this method in treating patients, - sometimes some HSCT recipients face problems such as cardiovascular complications. Therefore, this systematic review and meta-analysis aimed to evaluate the prevalence of cardiovascular complications in post-transplant patients.

Method

In order to review the published studies, we examined PubMed, MEDLINE, Cochrane Library, Scopus, and web of science databases from the beginning to the end of January 2022, and we used tools by the Newcastle–Ottawa Scale to evaluate the quality of the studies.

Result

In this study, 37 articles were included in the meta-analysis and 30,957 patients were examined. Also, the mean age of patients was 35.37 years. Based on the results of the meta-analysis, the prevalence of cardiovascular disease (CVD), was 16.84%. In addition, other complications related to CVD which include Arrhythmias, Congestive Heart Failure (CHF), Hypertension, stroke, and mortality were examined in patients who had hematopoietic stem cell transplantation and the resulting amounts were 3.91%, 3.66, 17.71, 0.22%, and 1.53%, respectively.